

Synthetic Biology and Engineered Live Biotherapeutics: Toward Increasing System Complexity

Tanel Ozdemir,^{1,7} Alex J.H. Fedorec,^{1,3,7} Tal Danino,^{4,5,6} and Chris P. Barnes^{1,2,*}

¹Department of Cell and Developmental Biology, University College London, London WC1E 6BT, UK

²UCL Genetics Institute, University College London, London WC1E 6BT, UK

³Centre for Mathematics, Physics and Engineering in the Life Sciences and Experimental Biology, University College London, London WC1E 6BT, UK

⁴Department of Biomedical Engineering, Columbia University, New York City, NY 10027, USA

⁵Data Science Institute, Columbia University, New York, NY 10027, USA

⁶Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA

⁷These authors contributed equally

*Correspondence: christopher.barnes@ucl.ac.uk

<https://doi.org/10.1016/j.cels.2018.06.008>

Recent advances in synthetic biology and biological system engineering have allowed the design and construction of engineered live biotherapeutics targeting a range of human clinical applications. In this review, we outline how systems approaches have been used to move from simple constitutive systems, where a single therapeutic molecule is expressed, to systems that incorporate sensing of the *in vivo* environment, feedback, computation, and biocontainment. We outline examples where each of these capabilities are achieved in different human disorders, including cancer, inflammation, and metabolic disease, in a number of environments, including the gastrointestinal tract, the liver, and the oral cavity. Throughout, we highlight the challenges of developing microbial therapeutics that are both sensitive and specific. Finally, we discuss how these systems are leading to the realization of engineered live biotherapeutics in the clinic.

Introduction

Systemically administered drugs can often lead to significant off-target delivery, giving rise to high doses in unintended locations and toxic side effects (Bae and Park, 2011). The goal of targeted drug delivery is to maximize drug accumulation within a target area and minimize off-target effects. This requires four key components: a delivery vehicle, sufficient stability to reach the target site, retention within the intended site, and timely drug release for the effective function of the drug (Bae and Park, 2011). Recent advances in biotechnology have enabled the use of nanoparticles and biopolymers for targeted delivery and remote activation (Farokhzad and Langer, 2009; Timko et al., 2011), but these also face significant challenges (Kwon et al., 2012). The human microbiota refers to the ecosystem of microorganisms living on or within the human body, and is increasingly being implicated as a regulator of health and disease (Li et al., 2016; Wu et al., 2010; Vijay-Kumar et al., 2010; Wang et al., 2011). This community consists of a wide variety of well-tolerated microorganisms such as bacteria, yeast, and phages that occupy a large and interactive buffer zone between the host and the external environment. The habitability of niches in the body to such microorganisms can in principle allow for their use in the delivery of therapeutics in a targeted and controllable fashion. There are three broad approaches to achieve this: application of natural organisms that have therapeutic properties (live biotherapeutics), artificially assembled microbial consortia, and genetically engineered commensal microbes (herein referred to as engineered live biotherapeutics).

A live biotherapeutic is a product that contains a live microorganism and is applicable to the prevention, treatment, or cure of human diseases (Olle, 2013). The discovery of commensal relationships between microbes and humans led to the clinical investigation of the therapeutic effects of ingestion of natural microbial probiotic strains such as *Escherichia coli* Nissle 1917 (EcN) (Henker et al., 2007) and *Lactobacillus* (Grüber et al., 2007; Drouault-Holowacz et al., 2008). The development of live biotherapeutic products (LBPs) is rapidly evolving. Historically, exploration of these strains was confined to the fields of microbiology and nutritional supplementation. The most commonly used microorganisms were those closely linked to food processing, such as *Lactobacillus* spp., *Bifidobacterium* spp., and *Saccharomyces*. The increasingly fine-detailed characterization of the human microbiota is leading to the identification of many other strains for therapeutic interventions, including *Bacillus* spp., *Weissella* spp., and *E. coli* (O'Toole et al., 2017). Another development is in the use of symbiotics, a combination of a probiotic and a prebiotic, with a recent study demonstrating that *Lactobacillus plantarum* plus fructooligosaccharide can prevent infant sepsis in a randomized placebo-controlled trial (Panigrahi et al., 2017).

It is becoming increasingly apparent that the host-microbiota interaction constitutes a complex ecosystem between the microbes and the immune system. The potential benefit of communities of probiotic bacteria has been recognized for some time, although their effectiveness has yet to be conclusively demonstrated (Chapman et al., 2011). A classic example is the VL#3






Figure 1. Targets for Engineered Live Biotherapeutics in the Gastrointestinal Tract

The gastrointestinal tract is an example of an environment in which live biotherapeutics can provide targeted benefit. Engineered strains have been designed to target (a) pathogenic microbes, (b) molecules that may lead to pathological condition, and (c) specific disease states.

formulation of eight strains of *Bifidobacterium*, *Lactobacillus*, and *Streptococcus*, which is prescribed for inflammatory bowel disease. More recently, the clinical potential of wild-type bacterial communities was demonstrated through the use of fecal microbiota transplantation in combating recurrent *Clostridium difficile* infections (van Nood et al., 2013). Leading on from these findings, Seres Therapeutics (MA) is running human clinical trials with an oral drug cocktail mimicking the wild-type bacterial composition of these fecal transplants (Khanna et al., 2016).

The third approach, and the main focus of this review article, is to leverage the tools of synthetic biology to engineer microbes and their communities to perform targeted therapeutic delivery with much greater control of location and timing. This approach has many advantages over the other two, including the ability to direct therapeutics to particular niches, ultimately allowing for higher doses with lower systemic effects (Claesen and Fischbach, 2014). In addition, the reciprocal interactions between the microbiota, immune system, diet, and genome makes it extremely difficult to distinguish cause and effect in several pathologies (Cerf-Bensussan and Gaboriau-Routhiau, 2010; Serino et al., 2012; Blekhman et al., 2015). Engineered microbes can be used to explore these interactions and modulate their effects, opening up many avenues to new biology and, ultimately, new therapeutic strategies.

In this review, we begin by outlining foundational work in the therapeutic use of engineered bacteria then discuss the latest synthetic and systems biology approaches taken with engineered live biotherapeutics for human health. We discuss the complexity of these methods and future directions in which cutting-edge synthetic biology can enable the design of robust and multi-layered system tools to effectively engineer the human microbiome for therapeutics.

Constitutive Therapeutic Delivery Systems

A fundamental approach in engineering microorganisms is the constitutive expression of an effector protein. Upon ingestion

and colonization with an engineered commensal strain, the protein produced directly acts upon the host or the resident microbial population to elicit a physiological response (Figure 1). This method has been used to target several different conditions, such as obesity (Chen et al., 2014), diabetes (Duan et al., 2008), colitis (Steidler et al., 2000), cancer (Yoon et al., 2017; Forbes, 2010), and infection by pathogenic bacteria (Focareta et al., 2006; Liu et al., 2016) (Table 1). A recent example includes the engineering of

Salmonella typhimurium to express the *Vibrio vulnificus* flagellin protein to act as a toll-like receptor ligand, triggering an immunogenic anti-cancer response from the host (Zheng et al., 2017). A further example of this approach involved the use of engineered EcN to disrupt the quorum sensing pathways of *Vibrio cholerae* (Duan & March 2010). This pathogen is known to control its population density and the amount of cholera toxin being produced via quorum sensing molecules cholera autoinducer 1 (CAI-1) and autoinducer 2 (AI-2). At high concentrations of both CAI-1 and AI-2, virulence factors such as cholera toxin are no longer expressed. To reduce virulence, EcN was transformed with a plasmid that constitutively expresses CqsA, the gene for CAI-1. In a mouse model, the ingestion of this engineered strain before *V. cholerae* administration significantly reduced cholera toxin production and mortality (Duan & March 2010). Another recent study demonstrated EcN harboring a modular expression system that could produce seven different antimicrobial proteins to target several gastrointestinal pathogens in the intestines (Geldart et al., 2016). An exciting approach to colorectal cancer chemoprevention was recently detailed in which EcN was engineered to express histone-like protein A (HlpA) on the cell surface, allowing it to bind to cancer cells with upregulated heparan sulfate proteoglycan (HSPG) on their cell surface (Ho et al., 2018). At the same time, the engineered bacteria secreted an enzyme, myrosinase, which converts dietary glucosinolate from cruciferous vegetables into the known anti-cancer molecule sulforaphane. This system was capable of killing colorectal cancer cell lines *in vitro* and preventing tumor progression in a murine colorectal cancer model (Ho et al., 2018).

In these constitutive expression systems, the amount of therapeutic delivered depends on several factors, such as the population size of the engineered microorganism. The parameter that is perhaps most under the control of the system designer is the strength of the promoter. A number of different constitutive promoters have been used, such as the lac (Paton et al., 2005), tac (Chaudhari et al., 2017), fliC (Duan & March 2010), slpA (Duan

Table 1. Constitutive Therapeutic Delivery Systems

Target	Location	Model Organism	Chassis	Mechanism	Reference
Cancer	GI tract	mouse	<i>Bifidobacterium longum</i>	production of Tumstatin, inhibiting proliferation & inducing apoptosis of tumorous vascular endothelial cells	Wei et al., 2016
Cancer	GI tract	mouse	<i>E. coli</i>	production of tumor-specific modular synthetic adhesins to enhance targeting	Piero-Lambea et al., 2015
Cancer	GI tract	mouse	<i>E. coli</i> Nissle 1917	expression of HlpA to enable specific binding to cancer cell & secretion of myrosinase to convert dietary glucosinolates to sulforaphane	Ho et al., 2018
Cancer	mammaryes	rat & guinea pig	<i>B. longum</i>	production of an enzyme to convert pro-drug 5-fluorocytosine to the toxic 5-FU within tumors	Sasaki et al., 2006
Cancer	subcutaneous	mouse	<i>S. typhimurium</i>	production of IFN- γ to enhance melanoma cell death after invasion	Yoon et al., 2017
Cholesterol	GI tract	human	<i>Lactobacillus reuteri</i>	reduction of absorption of non-cholesterol sterols by bile salt hydrolase-active capsules	Jones et al., 2012
Colitis	GI tract	mouse	<i>Lactococcus lactis</i>	secretion of immunosuppressive cytokine IL-27	Hanson et al., 2014
Colitis	GI tract	mouse	<i>L. lactis</i>	treatment of Crohn's disease by expressing IL-10	Steidler et al., 2000
Diabetes	GI tract	rat	<i>Lactobacillus gasseri</i>	secretion of GLP-1(1-37) to stimulate conversion of intestinal epithelial cells to insulin-secreting cells	Duan et al., 2015
<i>E. coli</i>	GI tract	mouse	<i>Lactobacillus casei</i>	expression of hLF to protect the host against bacterial infection	Chen et al., 2010
Enterotoxigenic <i>E. coli</i>	GI tract	rabbit	<i>E. coli</i>	production of chimeric LPS capable of binding heat-labile enterotoxin	Paton et al., 2005
<i>Helicobacter pylori</i>	GI tract	mouse	<i>Bacillus subtilis</i>	display of <i>H. pylori</i> urease B protein on spore coat	Zhou et al., 2015
HIV	vaginal tract	mouse	<i>E. coli</i> Nissle 1917	production of an antiviral peptide (HIV-gp41-hemolysin A) that blocks HIV entry	Rao et al., 2005
HIV	vaginal tract	–	<i>Streptococcus</i>	expression of an antiviral protein to block entry of HIV into the vaginal mucosa	Giomarelli et al., 2002
Liver disease	GI tract	rat	<i>E. coli</i> Nissle 1917	secretion of PQQ to prevent ethanol-induced oxidative damage in liver & other tissues	Singh et al., 2014
Lyme disease	GI tract	mouse	<i>S. typhimurium</i>	expression of a major surface protein, OspA, to enable the production of anti-OspA antibodies	Dunne et al., 1995
Mucosal injuries	GI tract	–	<i>E. coli</i> Nissle 1917	production of human EGF & lipase ABC transporter recognition domain to enhance wound healing	Choi et al., 2012
Obesity	GI tract	mouse	<i>E. coli</i> Nissle 1917	expression of NAPE, a lipid hormone that is released in response to food in the intestines	Chen et al., 2014
<i>S. enteritidis</i>	GI tract	turkey	<i>E. coli</i> Nissle 1917	secretion of the bacteriocin microcin J25	Forkus et al., 2017
<i>S. typhimurium</i>	GI tract	mouse	<i>B. longum</i>	display of <i>Salmonella</i> -antigen protects mice against <i>S. typhimurium</i> in a murine typhoid model	Yamamoto et al., 2010
Streptococcal	oral cavity	rat	<i>Lactobacillus</i>	expression of an antibody fragment which recognizes a streptococcal antigen	Krüger et al., 2002
Tetanus	GI tract & nasal	mouse	<i>L. plantarum</i>	production of tetanus toxin fragment for mouse immunization	Shaw et al., 2000
<i>V. cholerae</i>	GI tract	mouse	<i>E. coli</i>	production of chimeric LPS capable of binding cholera toxin	Focareta et al., 2006
<i>V. cholerae</i>	GI tract	mouse	<i>E. coli</i> Nissle 1917	expression of cholera AI 1 (CAI-1) to prevent <i>V. cholerae</i> virulence gene expression	Duan & March 2010

5-FU, 5-fluorouracil; GI, gastrointestinal; hLF, human lactoferrin; IL, interleukin; LPS, lipopolysaccharide; PQQ, pyrroloquinoline quinone.

et al., 2015), and Anderson promoters (Ho et al., 2018). Rarely is any reason for promoter choice given and often it seems to be due to ease of cloning rather than consideration for promoter strength. It has been shown that using a weaker promoter, with a lower metabolic burden, can lead to an increased therapeutic yield (Din et al., 2016) and, as such, greater consideration of promoter strength should be intrinsic to system design.

The export of active therapeutics from the engineered microorganism into the environment has been approached in two ways: by lysing the producing cells to release the intra-cellular therapeutic or by using secretion machinery to transport the therapeutic out of the cell. Lysis is generally not used in simpler systems as there needs to be a mechanism for ensuring lysis only occurs once enough protein has been produced within a cell or once a desired population density has been reached (Din et al., 2016). Several secretion mechanisms have been used and often those already present in the bacterial strain are commandeered, such as ABC transporters (Choi et al., 2012; Geldart et al., 2016), Sec systems (Zheng et al., 2017), and the flagellar secretion apparatus (Duan et al., 2008; Gupta et al., 2013). However, it should be noted that the efficiency of secretion of active folded proteins is not 100%, with the flagellar system secreting as little as 5% of total protein produced (Gupta et al., 2013). As such, consideration needs to be taken as to whether pushing cells to express as much of a therapeutic protein as possible is sensible if it cannot be exported into the environment.

A synthetic circuit, whether a simple constitutive expression system or a more complex system, will place a burden on the host microorganism. The greater the burden, the greater the selective pressure to remove the system or to develop mutations that reduce its function (Sleight and Sauro, 2013). Tools to help us understand how designed synthetic circuits will interact with their bacterial hosts (Weiße et al., 2015; Liao et al., 2017) and methods to identify less burdensome designs (Cerone et al., 2015) are being developed. A system has been engineered that attempts to reduce the metabolic burden on the host by limiting the production of a protein until the host has grown enough and there is sufficient substrate in the environment (Lo et al., 2016). However, this approach subsequently changes the dynamics of gene expression and, therefore, may not be appropriate for more complex systems with tighter parameter requirements.

While these approaches are developing alongside our understanding of disease biology, they solely capitalize on the capability of the engineered strains to transiently occupy the relevant niche, such as the intestines or the hypoxic microenvironment of a tumor, and recombinantly express a protein. However, bacteria also occupy niches other than those desired. When administered intravenously, bacteria can be found in a range of organs, including the spleen, kidneys, liver, brain, lungs, and heart (Forbes et al., 2003; Zheng et al., 2017). If an LBP was engineered to constitutively express an anti-cancer drug, low-level accumulation in untargeted healthy tissue would lead to systemic toxicity (Forbes et al., 2003; Forbes, 2010). An example in which a constitutive expression system showed off-target effects was in the delivery of a therapeutic gene to epithelial cells in a mouse model of colitis (Castagliuolo et al., 2005). In this case, a system was developed where a non-pathogenic *E. coli* strain could invade

epithelial cells and deliver functional DNA. However, when the gene was expressed constitutively, transcripts of the therapeutic gene were discovered in other tissues. Replacing the constitutive promoter with an inflammation-inducible promoter led to the mRNA transcripts only being detectable within the inflamed tissue. In line with this, there has been a subsequent effort to design systems that can detect and respond to environmental factors for regulated expression. These systems could enable the production of therapeutic proteins to be targeted to specific locations through the sensing of environmental stimuli, and to regulate expression using feedback to prevent overproduction.

Systems Approaches with Increased Functionality

Through the integration of synthetic biology tools and circuit design principles, researchers have been able to devise and implement systems approaches with greater complexity (Table 2, Figure 2). An underlying thread of these efforts is the use of robust biological components and system designs to create reproducible and consistent outcomes. Insulation of promoters (Davis et al., 2011) and ribosome binding sites (Lou et al., 2012) reduce the contextual effects of the surrounding DNA sequences, allowing for greater interchangeability of parts. Furthermore, the development of standardized transcription and translation elements (Mutalik et al., 2013), and terminators (Chen et al., 2013), has improved our ability to produce circuits that behave predictably. The use of computational methods to determine the optimal strengths of components or optimal circuit designs to produce desired behaviors (Otero-Muras and Banga, 2017; Leon et al., 2016; Woods et al., 2016), in conjunction with these more reliable parts, has allowed the pace of development and attainable complexity to greatly increase.

Systems that Can Sense and Respond

The next step up in complexity from the simple design of an engineered strain expressing a recombinant effector protein is a system that can detect a stimulus and produce a designated response (Figure 2). The stimuli can be detectable molecules or conditions in the host environment, or externally provided signals. This approach enables a more precisely localized or timed effect on the host. Such spatiotemporal control is a vital facet in the design of a therapeutic product.

A system capable of detecting native, therapeutically relevant stimuli was demonstrated using *Lactococcus lactis* to treat *Enterococcus faecium* infection (Borrero et al., 2015). The *L. lactis* strain was engineered to produce an antimicrobial bacteriocin when it detected the cCF10 enterococcal sex pheromone produced by *E. faecium*. Similar systems have been developed to sense and destroy *Pseudomonas aeruginosa* using engineered *E. coli* (Saeidi et al., 2011; Gupta et al., 2013). These both involved production of an antimicrobial bacteriocin upon detection of a quorum sensing molecule from *P. aeruginosa*, followed by release of the bacteriocin, either through lysis (Saeidi et al., 2011) or the use of a secretion tag (Gupta et al., 2013). The system of Saeidi et al. (2011) has been expanded to include the rewiring of the CheZ chemotaxis pathway to respond to the quorum sensing molecules produced by *P. aeruginosa* (Hwang et al., 2013), plus the incorporation of the anti-biofilm dispersin B protein (Hwang et al., 2017).

The collection of available sensors to detect therapeutically relevant information is expanding. Sensors for markers of gut

Table 2. Complex Live Biotherapeutic Systems

Target	Location	Model Organism	Chassis	Mechanism	Reference
Cancer	liver	mouse	<i>E. coli</i> Nissle 1917	engineered strain secretes an enzyme to cleave a substrate that can be detected in urine	Danino et al., 2015
Cancer	subcutaneous and liver	mouse	<i>S. typhimurium</i>	synchronized population lysis to release triple combination of cancer therapeutics	Din et al., 2016
Cancer	liver	mouse	<i>S. typhimurium</i>	quorum sensing to only produce protein when population threshold has been reached, reducing off-target therapeutic delivery	Swofford et al., 2015
Cancer	subcutaneous	mouse	<i>S. typhimurium</i>	inducible expression of FlaB in tumor tissue to stimulate an immune response	Zheng et al., 2017
Colitis	GI tract	mouse	<i>E. coli</i>	use <i>inv</i> to invade intestinal mucosal cells and deliver therapeutic under control of inflammation-inducible promoter	Castagliuolo et al., 2005
Enterohemorrhagic <i>E. coli</i>	–	<i>Galleria mellonella</i>	bacteriophage	delivery of CRISPR-Cas9-based, targeted antimicrobial	Citorik et al., 2014
Fever	subcutaneous and GI tract	mouse	<i>E. coli</i>	use thermo-sensitive promoters to detect fever and remote-control gene expression using ultrasound	Piraner et al., 2017
Inflammation	GI tract	mouse	<i>E. coli</i>	phage-lambda-based memory circuit to record markers of inflammation, stable for 200 days <i>in vivo</i>	Riglar et al., 2017
Inflammation	GI tract	mouse	<i>E. coli</i> Nissle 1917	detection of inflammation using tetrathionate and thiosulfate sensors	Daeffler et al., 2017
Inflammation and glycosuria	–	–	<i>E. coli</i>	thresholding, digitizing, and amplifying circuit for the sensitive detection of nitrogen oxides and glucose in pathological samples	Courbet et al., 2015
<i>P. aeruginosa</i>	GI tract	<i>Caenorhabditis elegans</i> and mouse	<i>L. casei</i>	sense quorum molecule and produce bacteriocin and dispersin B for lysing	Hwang et al., 2017
<i>S. aureus</i>	skin	mouse	bacteriophage	delivery of CRISPR-Cas9-based, targeted antimicrobial	Bikard et al., 2014
FlaB, flagellin B.					

inflammation, such as nitric oxide (Archer et al., 2012), thiosulfate, and tetrathionate (Daeffler et al., 2017), have been developed. A thermo-sensitive expression system has also been demonstrated to be able to detect a fever in a mouse model (Piraner et al., 2017).

The rapid advancement of bioinformatics tools and genome sequencing has enabled the discovery of novel sensors but other approaches are also possible. A series of modular transcription factors have been developed in which ligand binding domains, which recognize different sugars, can be attached to a DNA binding domain to produce novel repressors (Shis et al., 2014). A more general modular approach, using single-domain antibodies coupled to a DNA binding domain, has recently been described that aims to vastly increase the repertoire of ligands that can be detected (Chang et al., 2017). Tools such as feedback-regulated evolution of phenotype (FREP) (Chou and Keasling, 2013) or

compartmentalized partnered replication (Ellefson et al., 2014) can be used to evolve more responsive sensors.

In addition to the detection of native molecules and conditions, a number of systems have been developed that allow for deliberate, external stimulation. This was demonstrated in mice with EcN where a luminescent reporter circuit was controlled with the ingestion of synthetic inducers in drinking water (Loessner et al., 2009). In an alternative approach, a synthetic circuit in EcN enabled the strain to sense an *in vivo* liver metastasis signal and report on the finding with an easily detectable reporter in urine (Danino et al., 2015). In addition to being able to sense host fever, the thermo-sensitive expression system mentioned previously was shown to be capable of being induced externally through ultrasound (Piraner et al., 2017).

Instead of transiently occupying a destined niche after ingestion or intravenous injection, live biotherapeutics can also be




Figure 2. Increasing Complexity of Synthetic Systems Allows for Improved Levels of Control and Robustness

Constitutive production of a therapeutic from a host is the simplest form of engineered live biotherapeutic. Linking expression of the therapeutic to an exogenous signal allows for more spatially or temporally targeted delivery. Logic circuits allow for the integration of several exogenous signals, enabling greater control and robustness. Incorporating memory and clock systems further expands the computational capabilities of engineered strains. Similarly, incorporating signaling systems, allowing communication, allows for synchronized behavior. With several orthogonal communication systems, complex heterogeneous engineered populations can be built that allow for distribution of function.

engineered to invade the surrounding host cells in response to environmental signals. Engineered invasiveness paves the way for new drug delivery strategies with a more precise targeting capability. Using the invasin coding *inv* gene from *Yersinia pseudotuberculosis*, several groups have shown the ability of engineered bacteria to invade host cells. The *inv* invasion system was shown to allow engineered *E. coli* to invade intestinal mucosal cells after colonization (Critchley et al., 2004) and even deliver a therapeutic gene under an inflammation-inducible promoter (Castagliuolo et al., 2005). A further approach was shown that incorporated the *inv* gene into a quorum sensing circuit to create a live biotherapeutic that only invaded tumors after a certain population density was reached (Anderson et al., 2006).

Species from the *Bacteroides* genus are now known to be much more abundant and stable in the human intestinal microbiota than model strains such as *E. coli* and *S. typhimurium*, which are only capable of occupying the niche transiently (Human Microbiome Project Consortium, 2012). However, *Bacteroides* does not possess a rich library of cataloged genetic parts like those of the model strains (Mutalik et al., 2013) and therefore poses a greater challenge to engineer. In light of their relative stature in the intestines, the therapeutic functionality of *Bacteroides* strains with complex synthetic circuits has the potential to be much wider than that of model strains. In a demonstration of the expanding toolbox for engineering *Bacteroides*, a series of orthogonal inducible promoters using rhamnose, chondroitin sulfate, arabinogalactan, and isopropyl β -D-1-thiogalactopyranoside (IPTG) were designed and characterized (Mimee et al., 2015). Furthermore, the rhamnose inducible system was coupled with an integrase element to create an inducible memory switch that detected and recorded *in vivo* the addition of the sugar into the diet of the colonized mice. In a more recent example, a finely tuned anhydrotetracycline (aTc) promoter system with a 9,000-fold dynamic range was characterized in *Bacteroides* (Lim et al., 2017). Due to aTc being a synthetic inducer not found naturally in the mouse diet or microbiota, it is possible to use this system to precisely investigate dynamic host-microbe interactions. In this case, the inducible system was used in *Bacteroides* to investigate the effect of sialidase expression on the liberation of host mucosal sialic acid, a nutrient linked to pathogens such as antibiotic-associated *C. difficile* (Ng et al., 2013).

Systems with Feedback

The overproduction of certain therapeutic molecules can cause harm. If an engineered strain is designed to express a therapeutic protein, either constitutively or through induction, without consideration for the concentration of that protein currently in the environment, there is a risk of overproduction. Designing a system with feedback, in which the system senses its effect on the environment and uses that information to modulate its expression, prevents overexpression.

An example of a system in which feedback could be used is a circuit that responds to the production of butyrate in the gut. The short-chain fatty acid butyrate is beneficial for gut health (Hamer et al., 2009; Furusawa et al., 2013), and therapeutic approaches have been demonstrated with butyrate-producing strains (Geirnaert et al., 2017). Furthermore, synthetic systems have been used to produce butyrate in *E. coli* (Saini et al., 2014). However, there is also evidence that high levels of butyrate have an adverse effect on the intestines (Hamer et al., 2008). In this example, the use of a butyrate sensor in the system could be used to provide feedback on the level of butyrate in the environment and turn off butyrate production when a threshold is met.

In addition to the problems caused by protein overproduction, overgrowth of the engineered bacterial strains themselves can set off a systemic inflammatory response in the host. Feedback can be used to control population density and prevent population overgrowth. An example of this form of population feedback and control was demonstrated with a clinically relevant strain of *S. typhimurium* (Din et al., 2016). Using a quorum sensing system, previously developed to produce synchronized population oscillations (Danino et al., 2010; Prindle et al., 2011, 2012), a synchronized lysis circuit was developed that enabled the population to repeatedly grow and lyse in a synchronous fashion once a population threshold was reached. This system was used to deliver three cancer therapeutics in a mouse hepatic colorectal metastases model while the population density feedback prevented overgrowth of the bacterial population (Din et al., 2016).

Systems that Compute

To mimic the complexity of some natural responses to external stimuli, researchers are incorporating novel biological components into synthetic circuits that allow strains to integrate multiple signals and perform higher order functionalities (Figure 2).

Table 3. Modules Available for Building Computational Synthetic Circuits

Module Function	Mechanism
Boolean logic	transcriptional (Nielsen et al., 2016), translational (Green et al., 2017), recombinase (Siuti et al., 2013)
Memory	recombinase/integrase (Yang et al., 2014; Mimee et al., 2015), toggle switch (Zhang et al., 2014), CRISPR (Sheth et al., 2017)
Oscillator	single cell (Stricker et al., 2008; Potvin-Trottier et al., 2016), population (Danino et al., 2010)
Amplifier	recombinase/integrase (Courbet et al., 2015; Bonnet et al., 2013), transcriptional (<i>hrp</i>) (Wang et al., 2014)
Counter	ribo-regulated transcriptional or recombinase cascade (Friedland et al., 2009)
Digitizer	recombinase/integrase (Courbet et al., 2015; Rubens et al., 2016)
Filter	spatial bandpass (Kong et al., 2017), recombinase-based bandpass (Rubens et al., 2016)

Through the rational design and coupling of genetic components, a plethora of examples exist demonstrating a wide spectrum of functionalities. The importance of being able to integrate multiple signals to control therapeutic delivery can be seen in a system developed to target obesity. An *EcN* strain engineered to secrete *N*-acylphosphatidylethanolamines (NAPEs) was able to reduce the obesity of mice fed a high-fat diet when added to drinking water (Chen et al., 2014). However, it has been shown that elevated levels of *N*-acylethanolamide, of which NAPEs are a precursor, in plasma and the brain led to decreased energy expenditure (Brown et al., 2012). By using multiple external stimuli, such as pH or levels of bile acids, to determine the location of the live biotherapeutic, future systems could limit NAPE production to key areas of the colon.

The most notable recent leap in the realization of complex circuits has been the automated design of transcriptional networks, as was demonstrated with Cello, which utilizes a specification language based on Verilog for implementing design of gene circuits that perform Boolean logic functions (Nielsen et al., 2016). Using this system, the authors were able to demonstrate a functioning three-input consensus circuit, involving 55 biological components. Circuits such as these allow for the integration of several stimuli, which in turn allows for greater control over therapeutic delivery. In addition to transcriptional logic gates, translational logic circuits are being developed (Rodrigo et al., 2012) with ever-increasing complexity (Green et al., 2017). With the addition of modules that provide functionality, such as memory (Yang et al., 2014), oscillation (Stricker et al., 2008), counting (Friedland et al., 2009), and orthogonal communication (Scott and Hasty, 2016), the diversity of types of computation that are theoretically possible is continually expanding (Table 3).

The incorporation of a phage-lambda-based memory circuit was used to show that an engineered *E. coli* strain could detect, record, and report on intestinal inflammation *in vivo* over 6 months (Riglar et al., 2017). Recombinase-based memory was used to create a simple finite state machine (Roquet et al., 2016), although returning to prior states does not yet seem to be possible using this method. New memory devices are being developed that allow for the recording of information over long periods of time on genomic “tape” using either CRISPR (Sheth et al., 2017) or recombinases (Farzadfar and Lu, 2014).

Integrating memory with logic gates allows for the construction of sequential logic circuits rather than solely the combinational logic that Cello enables. A conditioning system was constructed using a bistable toggle switch as a memory module that allowed for a pavlovian-like association to be built between

two unrelated inducible inputs such as salicylate (“food”) and arabinose (“ring”), and a specific fluorescent output (“salivation”) (Zhang et al., 2014). By taking advantage of a heterogeneous population response, the pavlovian-like response to the ring stimulus was only reinforced by rounds of simultaneous training with the food input.

The sensitivity of a live biotherapeutic is crucial to its function. The addition of an integrase switch element into a sensor circuit was shown to digitize and significantly improve the signal to noise ratio in the detection of pathological nitrate by an *E. coli* biosensor (Courbet et al., 2015). Using quorum sensing communication systems to link logic gates together in different bacteria allows for the distribution of parts of larger logic circuits across a population (Tamsir et al., 2011).

Systems that Modify Native Gene Expression

More recently, live biotherapeutics have been engineered that are capable of interfering with gene expression within the host genome or microbiome. This approach can allow the engineering of host or microbiota biology on a sequence-specific level. Initial attempts have consisted of *E. coli* or *S. typhimurium* expressing short hairpin RNAs (shRNAs) for trans-kingdom RNAi in mucosal tissues after intestinal colonization (Xiang et al., 2006; Guo et al., 2011). The demonstrations with *E. coli* showed that the system could be used in the intestinal epithelium to knock down the expression of *CTNNB1*, an oncogene implicit in the initiation of colorectal cancer (Xiang et al., 2006).

With recent advancements in the use of CRISPR-Cas technologies, it has also been possible to devise live biotherapeutic approaches to engineer the microbiome on a sequence-specific level. Through the use of phages that can inject DNA directly into bacterial cells, sequence-specific RNA-guided nucleases (RGNs) can be expressed that precisely target the host genome. This method was used to specifically differentiate virulent and avirulent *Staphylococcus aureus* and to function in an *in vivo* mouse skin colonization model after topical administration of engineered phage lysates (Bikard et al., 2014). In another recent example, engineered phages were used to target antibiotic resistance harboring Enterobacteriaceae (Citorik et al., 2014). In this example, it was also shown that *E. coli* could be engineered with conjugative plasmids to deliver RGNs to the surrounding bacterial population and subsequently control the composition of a synthetic consortium based on the presence of a single gene. With the capability of targeting specific genetic signatures, this approach provides the power to eventually engineer and remodel complex bacterial populations such as the intestinal microbiome with an incredible level of resolution and precision.




Figure 3. Biocontainment of Engineered Strains and Recombinant DNA Is a Significant Challenge

(A) Several efforts have been made to limit the environment under which engineered strains are viable through auxotrophy, temperature range, and pH level. Even if an engineered strain is no longer viable, the engineered DNA can prove to be a risk through horizontal gene transfer.
 (B) Producing a toxin from the engineered plasmid prevents survival of transformed wild bacteria.
 (C) Requiring specific proteins for replication of the engineered plasmid prevents the amplification of engineered DNA outside of specific strains.

Systems for Biocontainment

As with any therapy, safety concerns must be addressed when engineering live biotherapeutics. Several approaches have been developed to tackle the challenge of biocontainment; ensuring that any engineered strain is not allowed to escape from a well-defined environment (Figure 3A). The most often explored method is the use of an environmental input for the survival of the engineered strain. This is primarily achieved through the use of auxotrophic strains (Steidler et al., 2003); however, metabolic cross-feeding in environments such as the gut must be taken into consideration when designing the auxotroph (Germannodt et al., 2016). As such, auxotrophs that require supplementation with non-standard or synthetic amino acids for production of essential proteins have been developed that show greater robustness to escape (Mandell et al., 2015; Rovner et al., 2015). The Deadman and Passcode systems, although not auxotrophs, also require environmental input to enable survival (Chan et al., 2016). These work through the two-layered transcriptional repression of a toxic gene and the targeted degradation of an essential gene. This system, as with the auxotrophic systems, requires the delivery of a molecule into the environment. Another approach is to use an environmental input already present in the target environment but not present outside of it. The temperature-dependent production of an antitoxin, active against a constitutively produced toxin, was shown to reduce survival of engineered bacteria unless they were incubated at 37°C, even after having passed through the mouse gut (Piraner et al., 2017).

Preventing the escape of engineered bacteria into the environment is not the only biocontainment concern when designing engineered LBPs. The transfer of genes from the engineered strain to wild strains present in the environment is a further challenge that must be addressed. This is particularly problematic in the inflamed gut due to increased horizontal gene transfer (Stecher et al., 2012). The GeneGuard system takes a three-pronged approach to prevent the escape of engineered plasmids into wild species by designing a strain and plasmid that could not survive without each other (Wright et al., 2014). An auxotrophic strain was designed that could not survive without an essential gene encoded on the plasmid. This prevents the genetically modified strain ejecting the plasmid and outcompeting the

plasmid-carrying strain. Secondly, the plasmid produces a toxin that is nullified by a genetically produced antitoxin, preventing the survival of wild strains that acquire the plasmid (Figure 3B). Finally, the plasmid cannot replicate without a genetically encoded protein. This prevents the amplification of the engineered DNA if a wild strain manages to acquire the plasmid and not be susceptible to the toxin (Figure 3C).

Conclusions

The examples discussed here demonstrate that, as our understanding of host biology and circuit designs evolves, we can integrate a variety of approaches to devise live biotherapeutics that act in a systematic, precise, and robust manner. The growing repertoire of genetically tractable strains, genetic parts, and system design tools will enable us to target human pathologies such as cancer and metabolic conditions for which there is still an urgent unmet need. Increasing the complexity of live biotherapeutics can allow us to, in theory, bypass and overcome traditional hurdles to effective pharmaceutical therapeutics, such as cost, dosing, side effects, and efficient delivery. The ability to precisely control a mixed population of bacteria could also allow us to use engineered strains with communication modules that enable a tunable division of labor *in vivo*. However, it is also apparent that increasing the complexity of these systems could potentially hinder the therapeutic efficacy of engineered LBPs, particularly in respect to host metabolic burden and genetic circuit stability. The method of genetic engineering used is also critical in the clinical translation of LBPs. A number of different approaches have reached human clinical trials, including Intrexon's (VA) engineered *L. lactis* strain with chromosomal integration (Limaye et al., 2013) and Marina Biotech's (CA) engineered *E. coli* strain incorporating plasmid-based systems (Xiang et al., 2006). A topic of discussion is whether the use of plasmid-based approaches is safe considering the risk of horizontal gene transfer (Stecher et al., 2012) and the chance of mutations disrupting plasmid copy number and subsequently affecting the dose of the therapeutic. These clinical trials demonstrate that live biotherapeutics show great promise, emphasized by increased recent investment in this area of biotechnology (Olle, 2013; Maxmen, 2017). Although there are still regulatory challenges to be addressed, history is rife with examples of new technologies that faced similar issues, such as *in vitro* fertilisation, which then became widely accepted once the

potential dangers were studied and understood. Continued research into live biotherapeutics may not only provide clear biomedical advances in areas such as the treatment of cancer, obesity, and type 2 diabetes but may also allow the development of precision tools to facilitate experimental investigation. These tools will further elucidate the convoluted and multifaceted relationship between the human host, metabolome, and microbiota.

ACKNOWLEDGMENTS

T.O. is funded through the BBSRC LIDo Doctoral Training Partnership. A.J.H.F is funded through the UCL CoMPLEX Centre for Doctoral Training. T.D. was supported by an NIH R00 (CA197649) and DoD Era of Hope Award (BC160541). C.P.B. is supported through a Wellcome Trust Research Career Development Fellowship (097319/Z/11/Z).

REFERENCES

- Anderson, J.C., Clarke, E.J., Arkin, A.P., and Voigt, C.A. (2006). Environmentally controlled invasion of cancer cells by engineered bacteria. *J. Mol. Biol.* 355, 619–627.
- Archer, E.J., Robinson, A.B., and Sel, G.M. (2012). Engineered *E. coli* that detect and respond to gut inflammation through nitric oxide sensing. *ACS Synth. Biol.* 1, 451–457.
- Bae, Y.H., and Park, K. (2011). Targeted drug delivery to tumors: myths, reality and possibility. *J. Control. Release* 153, 198.
- Bikard, D., Euler, C.W., Jiang, W., Nussenzweig, P.M., Goldberg, G.W., Duportet, X., Fischetti, V.A., and Marraffini, L.A. (2014). Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. *Nat. Biotechnol.* 32, 1146–1150.
- Blekhman, R., Goodrich, J.K., Huang, K., Sun, Q., Bukowski, R., Bell, J.T., Spector, T.D., Keinan, A., Ley, R.E., Gevers, D., and Clark, A.G. (2015). Host genetic variation impacts microbiome composition across human body sites. *Genome Biol.* 16, 191.
- Bonnet, J., Yin, P., Ortiz, M.E., Subsoontorn, P., and Endy, D. (2013). Amplifying genetic logic gates. *Science* 340, 599–603.
- Borrero, J., Chen, Y., Dunny, G.M., and Kaznessis, Y.N. (2015). Modified lactic acid bacteria detect and inhibit multiresistant enterococci. *ACS Synth. Biol.* 4, 299–306.
- Brown, W.H., Gillum, M.P., Lee, H.-Y., Camperez, J.P.G., Zhang, X.-M., Jeong, J.K., Alves, T.C., Eron, D.M., Guigni, B.A., Kahn, M., et al. (2012). Fatty acid amide hydrolase ablation promotes ectopic lipid storage and insulin resistance due to centrally mediated hypothyroidism. *Proc. Natl. Acad. Sci. USA* 109, 14966–14971.
- Castagliuolo, I., Beggio, E., Brun, P., Barzon, L., Goussard, S., Manganelli, R., Grillot-Courvalin, C., and Pal, G. (2005). Engineered *E. coli* delivers therapeutic genes to the colonic mucosa. *Gene Ther.* 12, 1070–1078.
- Cerf-Bensussan, N., and Gaboriau-Routhiau, V. (2010). The immune system and the gut microbiota: friends or foes? *Nat. Rev. Immunol.* 10, 735–744.
- Ceroni, F., Algar, R., Stan, G.-B., and Ellis, T. (2015). Quantifying cellular capacity identifies gene expression designs with reduced burden. *Nat. Methods* 12, 415–418.
- Chan, C.T.Y., Lee, J.W., Cameron, D.E., Bashor, C.J., and Collins, J.J. (2016). ‘Deadman’ and ‘Passcode’ microbial kill switches for bacterial containment. *Nat. Chem. Biol.* 12, 82–86.
- Chang, H.-J., Mayonove, P., Zavala, A., De Visch, A., Minard, P., Cohen-Gonsaud, M., and Bonnet, J. (2017). A modular receptor platform to expand the sensing repertoire of bacteria. *ACS Synth. Biol.* 7, 166–175.
- Chapman, C.M.C., Gibson, G.R., and Rowland, I. (2011). Health benefits of probiotics: are mixtures more effective than single strains? *Eur. J. Nutr.* 50, 1–17.
- Chaudhari, A.S., Raghuvanshi, R., and Kumar, G.N. (2017). Genetically engineered *Escherichia coli* Nissle 1917 symbiotic counters fructose-induced metabolic syndrome and iron deficiency. *Appl. Microbiol. Biotechnol.* 101, 4713–4723.
- Chen, H.-L., Lai, Y.-W., Chen, C.-S., Chu, T.-W., Lin, W., Yen, C.-C., Lin, M.-F., Tu, M.-Y., and Chen, C.-M. (2010). Probiotic *Lactobacillus casei* expressing human lactoferrin elevates antibacterial activity in the gastrointestinal tract. *Biometals* 23, 543–554.
- Chen, Y.-J., Liu, P., Nielsen, A.A.K., Brophy, J.A.N., Clancy, K., Peterson, T., and Voigt, C.A. (2013). Characterization of 582 natural and synthetic terminators and quantification of their design constraints. *Nat. Methods* 10, 659–664.
- Chen, Z., Guo, L., Zhang, Y., Walzem, R.L., Pendergast, J.S., Printz, R.L., Morris, L.C., Matafonova, E., Stien, X., Kang, L., et al. (2014). Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity. *J. Clin. Invest.* 124, 3391–3406.
- Choi, H.J., Ahn, J.H., Park, S.-H., Do, K.H., Kim, J., and Moon, Y. (2012). Enhanced wound healing by recombinant *Escherichia coli* Nissle 1917 via human epidermal growth factor receptor in human intestinal epithelial cells: therapeutic implication using recombinant probiotics. *Infect. Immun.* 80, 1079–1087.
- Chou, H.H., and Keasling, J.D. (2013). Programming adaptive control to evolve increased metabolite production. *Nat. Commun.* 4, 2595.
- Citorik, R.J., Mimee, M., and Lu, T.K. (2014). Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. *Nat. Biotechnol.* 32, 1141–1145.
- Claesen, J., and Fischbach, M.A. (2014). Synthetic microbes as drug delivery systems. *ACS Synth. Biol.* 4, 358–364.
- Courbet, A., Endy, D., Renard, E., Molina, F., and Bonnet, J. (2015). Detection of pathological biomarkers in human clinical samples via amplifying genetic switches and logic gates. *Sci. Transl. Med.* 7, 289ra83.
- Critchley, R.J., Jezard, S., Radford, K.J., Goussard, S., Lemoine, N.R., Grillot-Courvalin, C., and Vassaux, G. (2004). Potential therapeutic applications of recombinant, invasive *E. coli*. *Gene Ther.* 11, 1224–1233.
- Daeffler, K.N.-M., Galley, J.D., Sheth, R.U., Ortiz-Velez, L.C., Bibb, C.O., Shroyer, N.F., Britton, R.A., and Tabor, J.J. (2017). Engineering bacterial thiosulfate and tetrathionate sensors for detecting gut inflammation. *Mol. Syst. Biol.* 13, 923.
- Danino, T., Mondragón-Palomino, O., Tsimring, L., and Hasty, J. (2010). A synchronized quorum of genetic clocks. *Nature* 463, 326–330.
- Danino, T., Prindle, A., Kwong, G.A., Skalak, M., Li, H., Allen, K., Hasty, J., and Bhatia, S.N. (2015). Programmable probiotics for detection of cancer in urine. *Sci. Transl. Med.* 7, 289ra84.
- Davis, J.H., Rubin, A.J., and Sauer, R.T. (2011). Design, construction and characterization of a set of insulated bacterial promoters. *Nucleic Acids Res.* 39, 1131–1141.
- Din, M.O., Danino, T., Prindle, A., Skalak, M., Selimkhanov, J., Allen, K., Julio, E., Atolia, E., Tsimring, L.S., Bhatia, S.N., and Hasty, J. (2016). Synchronized cycles of bacterial lysis for in vivo delivery. *Nature* 536, 81–85.
- Drouault-Holowacz, S., Bieuvelet, S., Burkel, A., Cazaubiel, M., Dray, X., and Marteau, P. (2008). A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. *Gastroenterol. Clin. Biol.* 32, 147–152.
- Duan, F., and March, J.C. (2010). Engineered bacterial communication prevents *Vibrio cholerae* virulence in an infant mouse model. *Proc. Natl. Acad. Sci. USA* 107, 11260–11264.
- Duan, F., Curtis, K.L., and March, J.C. (2008). Secretion of insulinotropic proteins by commensal bacteria: rewiring the gut to treat diabetes. *Appl. Environ. Microbiol.* 74, 7437–7438.
- Duan, F.F., Liu, J.H., and March, J.C. (2015). Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes. *Diabetes* 64, 1794–1803.
- Dunne, M., al-Ramadi, B.K., Barthold, S.W., Flavell, R.A., and Fikrig, E. (1995). Oral vaccination with an attenuated *Salmonella typhimurium* strain expressing

- Borrelia burgdorferi* OspA prevents murine Lyme borreliosis. *Infect. Immun.* 63, 1611–1614.
- Ellefson, J.W., Meyer, A.J., Hughes, R.A., Cannon, J.R., Brodbelt, J.S., and Ellington, A.D. (2014). Directed evolution of genetic parts and circuits by compartmentalized partnered replication. *Nat. Biotechnol.* 32, 97–101.
- Farokhzad, O.C., and Langer, R. (2009). Impact of nanotechnology on drug delivery. *ACS Nano.* 3, 16–20.
- Farzadfar, F., and Lu, T.K. (2014). Genomically encoded analog memory with precise *in vivo* DNA writing in living cell populations. *Science* 346, 1256272.
- Focareta, A., Paton, J.C., Morona, R., Cook, J., and Paton, A.W. (2006). A recombinant probiotic for treatment and prevention of cholera. *Gastroenterology* 130, 1688–1695.
- Forbes, N.S. (2010). Engineering the perfect (bacterial) cancer therapy. *Nat. Rev. Cancer* 10, 785–794.
- Forbes, N.S., Munn, L.L., Fukumura, D., and Jain, R.K. (2003). Sparse initial entrapment of systemically injected *Salmonella typhimurium* leads to heterogeneous accumulation within tumors. *Cancer Res.* 63, 5188–5193.
- Forkus, B., Ritter, S., Vlysidis, M., Geldart, K., and Kaznessis, Y.N. (2017). Antimicrobial probiotics reduce *Salmonella enterica* in Turkey gastrointestinal tracts. *Sci. Rep.* 7, 40695.
- Friedland, A.E., Lu, T.K., Wang, X., Shi, D., Church, G., and Collins, J.J. (2009). Synthetic gene networks that count. *Science* 324, 1199–1202.
- Furusawa, Y., Obata, Y., Fukuda, S., Endo, T.A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. (2013). Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. *Nature* 504, 446–450.
- Geirnaert, A., Calatayud, M., Grootaert, C., Laukens, D., Devriese, S., Smaghe, G., Vos, M.D., Boon, N., and Van de Wiele, T. (2017). Butyrate-producing bacteria supplemented *in vitro* to Crohn's disease patient microbiota increased butyrate production and enhanced intestinal epithelial barrier integrity. *Sci. Rep.* 7, 11450.
- Geldart, K., Forkus, B., McChesney, E., McCue, M., and Kaznessis, Y.N. (2016). pMPES: a modular peptide expression system for the delivery of antimicrobial peptides to the site of gastrointestinal infections using probiotics. *Pharmaceutics (Basel)* 9, 60.
- Germerodt, S., Bohl, K., Lück, A., Pande, S., Schröter, A., Kaleta, C., Schuster, S., and Kost, C. (2016). Pervasive selection for cooperative cross-feeding in bacterial communities. *PLoS Comput. Biol.* 12, e1004986.
- Giomarelli, B., Provvedi, R., Meacci, F., Maggi, T., Medaglini, D., Pozzi, G., Mori, T., McMahon, J.B., Gardella, R., and Boyd, M.R. (2002). The microbicide cyanovirin-N expressed on the surface of commensal bacterium *Streptococcus gordonii* captures HIV-1. *AIDS* 16, 1351–1356.
- Green, A.A., Kim, J., Ma, D., Silver, P.A., Collins, J.J., and Yin, P. (2017). Complex cellular logic computation using ribocomputing devices. *Nature* 548, 117–121.
- Grüber, C., Wendt, M., Sulser, C., Lau, S., Kulig, M., Wahn, U., Werfel, T., and Niggemann, B. (2007). Randomized, placebo-controlled trial of *Lactobacillus rhamnosus* GG as treatment of atopic dermatitis in infancy. *Allergy* 62, 1270–1276.
- Guo, H., Zhang, J., Inai, C., Nguyen, T., Fruehauf, J.H., Keates, A.C., and Li, C.J. (2011). Targeting tumor gene by shRNA-expressing *Salmonella*-mediated RNAi. *Gene Ther.* 18, 95–105.
- Gupta, S., Bram, E.E., and Weiss, R. (2013). Genetically programmable pathogen sense and destroy. *ACS Synth. Biol.* 2, 715–723.
- Hamer, H.M., Jonkers, D., Venema, K., Vanhoutvin, S., Troost, F.J., and Brummer, R.-J. (2008). Review article: the role of butyrate on colonic function. *Aliment. Pharmacol. Ther.* 27, 104–119.
- Hamer, H.M., Jonkers, D.M.A.E., Bast, A., Vanhoutvin, S.A.L.W., Fischer, M.A.J.G., Kodde, A., Troost, F.J., Venema, K., and Brummer, R.-J.M. (2009). Butyrate modulates oxidative stress in the colonic mucosa of healthy humans. *Clin. Nutr.* 28, 88–93.
- Hanson, M.L., Hixon, J.A., Li, W., Felber, B.K., Anver, M.R., Stewart, C.A., Janssens, B.M., Datta, S.K., Shen, W., McLean, M.H., et al. (2014). Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice. *Gastroenterology* 146, 210–221.
- Henker, J., Laass, M., Blokhin, B.M., Bolbot, Y.K., Maydannik, V.G., Elze, M., Wolff, C., and Schulze, J. (2007). The probiotic *Escherichia coli* strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. *Eur. J. Pediatr.* 166, 311–318.
- Ho, C.L., Tan, H.Q., Chua, K.J., Kang, A., Lim, K.H., Ling, K.L., Yew, W.S., Lee, Y.S., Thiery, J.P., and Chang, M.W. (2018). Engineered commensal microbes for diet-mediated colorectal-cancer chemoprevention. *Nat. Biomed. Eng.* 2, 27.
- Human Microbiome Project Consortium (2012). Structure, function and diversity of the healthy human microbiome. *Nature* 486, 207–214.
- Hwang, I.Y., Tan, M.H., Koh, E., Ho, C.L., Poh, C.L., and Chang, M.W. (2013). Reprogramming microbes to be pathogen-seeking killers. *ACS Synth. Biol.* 3, 228–237.
- Hwang, I.Y., Koh, E., Wong, A., March, J.C., Bentley, W.E., Lee, Y.S., and Chang, M.W. (2017). Engineered probiotic *Escherichia coli* can eliminate and prevent *Pseudomonas aeruginosa* gut infection in animal models. *Nat. Commun.* 8, 15028.
- Jones, M.L., Martoni, C.J., and Prakash, S. (2012). Cholesterol lowering and inhibition of sterol absorption by *Lactobacillus reuteri* NCIMB 30242: a randomized controlled trial. *Eur. J. Clin. Nutr.* 66, 1234–1241.
- Khanna, S., Pardi, D.S., Kelly, C.R., Kraft, C.S., Dhore, T., Henn, M.R., Lombardo, M.-J., Vulic, M., Ohsumi, T., Winkler, J., et al. (2016). A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent *Clostridium difficile* infection. *J. Infect. Dis.* 214, 173–181.
- Kong, W., Blanchard, A.E., Liao, C., and Lu, T. (2017). Engineering robust and tunable spatial structures with synthetic gene circuits. *Nucleic Acids Res.* 45, 1005–1014.
- Krüger, C., Hu, Y., Pan, Q., Marcotte, H., Hultberg, A., Delwar, D., van Dalen, P.J., Pouwels, P.H., Leer, R.J., et al. (2002). In situ delivery of passive immunity by lactobacilli producing single-chain antibodies. *Nat. Biotechnol.* 20, 702–706.
- Kwon, I.K., Lee, S.C., Han, B., and Park, K. (2012). Analysis on the current status of targeted drug delivery to tumors. *J. Control. Release* 164, 108–114.
- Leon, M., Woods, M.L., Fedorec, A.J., and Barnes, C.P. (2016). A computational method for the investigation of multistable systems and its application to genetic switches. *BMC Syst. Biol.* 10, 130.
- Li, D., Achkar, J.-P., Haritunians, T., Jacobs, J.P., Hui, K.Y., D'Amato, M., Brand, S., Radford-Smith, G., Halfvarson, J., Niess, J.-H., et al. (2016). A pleiotropic missense variant in SLC39A8 is associated with Crohn's disease and human gut microbiome composition. *Gastroenterology* 151, 724–732.
- Liao, C., Blanchard, A.E., and Lu, T. (2017). An integrative circuit-host modeling framework for predicting synthetic gene network behaviours. *Nat. Microbiol.* 2, 1658.
- Lim, B., Zimmermann, M., Barry, N.A., and Goodman, A.L. (2017). Engineered regulatory systems modulate gene expression of human commensals in the gut. *Cell* 169, 547–558.
- Limaye, S.A., Haddad, R.I., Cilli, F., Sonis, S.T., Colevas, A.D., Brennan, M.T., Hu, K.S., and Murphy, B.A. (2013). Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. *Cancer* 119, 4268–4276.
- Liu, W., Tan, Z., Xue, J., Luo, W., Song, H., Lv, X., Zheng, T., Xi, T., and Xing, Y. (2016). Therapeutic efficacy of oral immunization with a non-genetically modified *Lactococcus lactis*-based vaccine CUE-GEM induces local immunity against *Helicobacter pylori* infection. *Appl. Microbiol. Biotechnol.* 100, 6219–6229.
- Lo, T.-M., Chng, S.H., Teo, W.S., Cho, H.-S., and Chang, M.W. (2016). A two-layer gene circuit for decoupling cell growth from metabolite production. *Cell Syst.* 3, 133–143.
- Loessner, H., Leschner, S., Endmann, A., Westphal, K., Wolf, K., Kochruebe, K., Miloud, T., Altenbuchner, J., and Weiss, S. (2009). Drug-inducible remote control of gene expression by probiotic *Escherichia coli* Nissle 1917 in intestine, tumor and gall bladder of mice. *Microbes Infect.* 11, 1097–1105.

- Lou, C., Stanton, B., Chen, Y.-J., Munsky, B., and Voigt, C. (2012). Ribozyme-based insulator parts buffer synthetic circuits from genetic context. *Nat. Biotechnol.* 30, 1137–1142.
- Mandell, D.J., Lajoie, M.J., Mee, M.T., Takeuchi, R., Kuznetsov, G., Norville, J.E., Gregg, C.J., Stoddard, B.L., and Church, G.M. (2015). Bioccontainment of genetically modified organisms by synthetic protein design. *Nature* 518, 55–60.
- Maxmen, A. (2017). Living therapeutics: scientists genetically modify bacteria to deliver drugs. *Nat. Med.* 23, 5–7.
- Mimee, M., Tucker, A.C., Voigt, C.A., and Lu, T.K. (2015). Programming a human commensal bacterium, *Bacteroides thetaiotaomicron*, to sense and respond to stimuli in the murine gut microbiota. *Cell Syst.* 1, 62–71.
- Mutalik, V.K., Guimaraes, J.C., Cambray, G., Lam, C., Christoffersen, M.J., Mai, Q.-A., Tran, A.B., Paull, M., Keasling, J.D., Arkin, A.P., and Endy, D. (2013). Precise and reliable gene expression via standard transcription and translation initiation elements. *Nat. Methods* 10, 354–360.
- Ng, K.M., Ferreyra, J.A., Higginbottom, S.K., Lynch, J.B., Kashyap, P.C., Goopinath, S., Naidu, N., Choudhury, B., Weimer, B.C., Monack, D.M., and Sonnenburg, J.L. (2013). Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. *Nature* 502, 96–99.
- Nielsen, A.A., Der, B.S., Shin, J., Vaidyanathan, P., Paralanov, V., Strychalski, E.A., Ross, D., Densmore, D., and Voigt, C.A. (2016). Genetic circuit design automation. *Science* 352, aac7341.
- van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E.G., de Vos, W.M., Visser, C.E., Kuijper, E.J., Bartelsman, J.F., Tijssen, J.G., et al. (2013). Duodenal infusion of donor feces for recurrent *Clostridium difficile*. *N. Engl. J. Med.* 368, 407–415.
- Olle, B. (2013). Medicines from microbiota. *Nat. Biotechnol.* 31, 309–315.
- Otero-Muras, I., and Banga, J.R. (2017). Automated design framework for synthetic biology exploiting pareto optimality. *ACS Synth. Biol.* 6, 1180–1193.
- O'Toole, P.W., Marchesi, J.R., and Hill, C. (2017). Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. *Nat. Microbiol.* 2, 17057.
- Panigrahi, P., Parida, S., Nanda, N.C., Satpathy, R., Pradhan, L., Chandel, D.S., and Chaudhry, R. (2017). A randomized symbiotic trial to prevent sepsis among infants in rural India. *Nature* 548, 407.
- Paton, A.W., Jennings, M.P., Morona, R., Wang, H., Focareta, A., Roddam, L.F., and Paton, J.C. (2005). Recombinant probiotics for treatment and prevention of enterotoxigenic *Escherichia coli* diarrhea. *Gastroenterology* 128, 1219–1228.
- Piñero-Lambea, C., Bodelón, G., Fernández-Periéñez, R., Cuesta, A.M., Álvarez-Vallina, L., and Fernández, L.Á. (2015). Programming controlled adhesion of *E. coli* to target surfaces, cells, and tumors with synthetic adhesins. *ACS Synth. Biol.* 4, 463–473.
- Piraner, D.I., Abedi, M.H., Moser, B.A., Lee-Gosselin, A., and Shapiro, M.G. (2017). Tunable thermal bioswitches for in vivo control of microbial therapeutics. *Nat. Chem. Biol.* 13, 75–80.
- Potvin-Trottier, L., Lord, N.D., Vinnicombe, G., and Paulsson, J. (2016). Synchronous long-term oscillations in a synthetic gene circuit. *Nature* 538, 514–517.
- Prindle, A., Samayoa, P., Razinkov, I., Danino, T., Tsimring, L.S., and Hasty, J. (2011). A sensing array of radically coupled genetic 'biopixels'. *Nature* 481, 39–44.
- Prindle, A., Selimkhanov, J., Danino, T., Samayoa, P., Goldberg, A., Bhatia, S.N., and Hasty, J. (2012). Genetic circuits in *Salmonella typhimurium*. *ACS Synth. Biol.* 1, 458–464.
- Rao, S., Hu, S., McHugh, L., Lueders, K., Henry, K., Zhao, Q., Fekete, R.A., Kar, S., Adhya, S., and Hamer, D.H. (2005). Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide. *Proc. Natl. Acad. Sci. USA* 102, 11993–11998.
- Riglar, D.T., Giessen, T.W., Baym, M., Kerns, S.J., Niederhuber, M.J., Bronson, R.T., Kotula, J.W., Gerber, G.K., Way, J.C., and Silver, P.A. (2017). Engineered bacteria can function in the mammalian gut long-term as live diagnostics of inflammation. *Nat. Biotechnol.* 35, 653–658.
- Rodrigo, G., Landrain, T.E., and Jaramillo, A. (2012). De novo automated design of small RNA circuits for engineering synthetic riboregulation in living cells. *Proc. Natl. Acad. Sci. USA* 109, 15271–15276.
- Roquet, N., Soleimany, A.P., Ferris, A.C., Aaronson, S., and Lu, T.K. (2016). Synthetic recombinase-based state machines in living cells. *Science* 353, aad8559.
- Rovner, A.J., Haimovich, A.D., Katz, S.R., Li, Z., Grome, M.W., Gassaway, B.M., Amiram, M., Patel, J.R., Gallagher, R.R., Rinehart, J., et al. (2015). Recoded organisms engineered to depend on synthetic amino acids. *Nature* 518, 89–93.
- Rubens, J.R., Selvaggio, G., and Lu, T.K. (2016). Synthetic mixed-signal computation in living cells. *Nat. Commun.* 7, 11658.
- Saeidi, N., Wong, C.K., Lo, T.-M., Nguyen, H.X., Ling, H., Leong, S.S.J., Poh, C.L., and Chang, M.W. (2011). Engineering microbes to sense and eradicate *Pseudomonas aeruginosa*, a human pathogen. *Mol. Syst. Biol.* 7, 521.
- Saini, M., Wang, Z.W., Chiang, C.-J., and Chao, Y.-P. (2014). Metabolic engineering of *Escherichia coli* for production of butyric acid. *J. Agric. Food Chem.* 62, 4342–4348.
- Sasaki, T., Fujimori, M., Hamaji, Y., Hama, Y., Ito, K.I., Amano, J., and Taniguchi, S. (2006). Genetically engineered *Bifidobacterium longum* for tumor-targeting enzyme-prodrug therapy of autochthonous mammary tumors in rats. *Cancer Sci.* 97, 649–657.
- Scott, S.R., and Hasty, J. (2016). Quorum sensing communication modules for microbial consortia. *ACS Synth. Biol.* 5, 969.
- Serino, M., Luche, E., Gres, S., Baylac, A., Berg, M., Cenac, C., Waget, A., Klopp, P., Iacovoni, J., Klopp, C., et al. (2012). Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota. *Gut* 61, 543–553.
- Shaw, D.M., Gaerth, B., Leer, R.J., Van Der Stap, J.G.M.M., Smitsenaar, C., Heijne Den Bak-Glashouwer, M.-J., Thole, J.E.R., Tielen, F.J., Pouwels, P.H., and Havenith, C.E.G. (2000). Engineering the microflora to vaccinate the mucosa: serum immunoglobulin G responses and activated draining cervical lymph nodes following mucosal application of tetanus toxin fragment C-expressing lactobacilli. *Immunology* 100, 510–518.
- Sheth, R.U., Yim, S.S., Wu, F.L., and Wang, H.H. (2017). Multiplex recording of cellular events over time on CRISPR biological tape. *Science* 358, 1457–1461.
- Shis, D.L., Hussain, F., Meinhardt, S., Swint-Kruse, L., and Bennett, M.R. (2014). Modular, multi-input transcriptional logic gating with orthogonal LacI/GalR family chimeras. *ACS Synth. Biol.* 3, 645.
- Singh, A.K., Pandey, S.K., and Naresh Kumar, G. (2014). Pyrroloquinoline quinone-secreting probiotic *Escherichia coli* Nissle 1917 ameliorates ethanol-induced oxidative damage and hyperlipidemia in rats. *Alcohol. Clin. Exp. Res.* 38, 2127–2137.
- Siuti, P., Yazbek, J., and Lu, T.K. (2013). Synthetic circuits integrating logic and memory in living cells. *Nat. Biotechnol.* 31, 448–452.
- Sleight, S.C., and Sauro, H.M. (2013). Visualization of evolutionary stability dynamics and competitive fitness of *Escherichia coli* engineered with randomized multigene circuits. *ACS Synth. Biol.* 2, 519–528.
- Stecher, B., Denzler, R., Maier, L., Bernet, F., Sanders, M.J., Pickard, D.J., Barthel, M., Westendorf, A.M., Krogfelt, K.A., Walker, A.W., et al. (2012). Gut inflammation can boost horizontal gene transfer between pathogenic and commensal Enterobacteriaceae. *Proc. Natl. Acad. Sci. USA* 109, 1269–1274.
- Steidler, L., Hans, W., Schotte, L., Neirynck, S., Obermeier, F., Falk, W., Fiers, W., and Remaut, E. (2000). Treatment of murine colitis by *Lactococcus lactis* secreting interleukin-10. *Science* 289, 1352–1355.
- Steidler, L., Neirynck, S., Huyghebaert, N., Snoeck, V., Vermeire, A., Goddeeris, B., Cox, E., Remon, J.P., and Remaut, E. (2003). Biological containment of genetically modified *Lactococcus lactis* for intestinal delivery of human interleukin 10. *Nat. Biotechnol.* 21, 785–789.
- Stricker, J., Cookson, S., Bennett, M.R., Mather, W.H., Tsimring, L.S., and Hasty, J. (2008). A fast, robust and tunable synthetic gene oscillator. *Nature* 456, 516–519.

- Swofford, C.A., Dessel, N.V., and Forbes, N.S. (2015). Quorum-sensing *Salmonella* selectively trigger protein expression within tumors. *Proc. Natl. Acad. Sci. USA* 112, 3457–3462.
- Tamsir, A., Tabor, J.J., and Voigt, C.A. (2011). Robust multicellular computing using genetically encoded nor gates and chemical ‘wires’. *Nature* 469, 212–215.
- Timko, B.P., Whitehead, K., Gao, W., Kohane, D.S., Farokhzad, O., Anderson, D., and Langer, R. (2011). Advances in drug delivery. *Annu. Rev. Mater. Res.* 41, 1–20.
- Vijay-Kumar, M., Aitken, J.D., Carvalho, F.A., Cullender, T.C., Mwangi, S., Srivivasan, S., Sitaraman, S.V., Knight, R., Ley, R.E., and Gewirtz, A.T. (2010). Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. *Science* 328, 228–231.
- Wang, Z., Klipfell, E., Bennett, B.J., Koeth, R., Levison, B.S., Dugar, B., Feldstein, A.E., Britt, E.B., Fu, X., Chung, Y.-M., et al. (2011). Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature* 472, 57–63.
- Wang, B., Barahona, M., and Buck, M. (2014). Engineering modular and tunable genetic amplifiers for scaling transcriptional signals in cascaded gene networks. *Nucleic Acids Res.* 42, 9484–9492.
- Wei, C., Xun, A.Y., Wei, X.X., Yao, J., Wang, J.Y., Shi, R.Y., Yang, G.H., Li, Y.X., Xu, Z.L., Lai, M.G., et al. (2016). Bifidobacteria expressing tumstatin protein for antitumor therapy in tumor-bearing mice. *Technol. Cancer Res. Treat.* 15, 498–508.
- Weißé, A.Y., Oyarzún, D.A., Danos, V., and Swain, P.S. (2015). Mechanistic links between cellular trade-offs, gene expression, and growth. *Proc. Natl. Acad. Sci. USA* 112, E1038–E1047.
- Woods, M.L., Leon, M., Perez-Carrasco, R., and Barnes, C.P. (2016). A statistical approach reveals designs for the most robust stochastic gene oscillators. *ACS Synth. Biol.* 5, 459.
- Wright, O., Delmans, M., Stan, G.-B., and Ellis, T. (2014). GeneGuard: a modular plasmid system designed for biosafety. *ACS Synth. Biol.* 4, 307–316.
- Wu, H.-J., Ivanov, I.I., Darce, J., Hattori, K., Shima, T., Umesaki, Y., Littman, D.R., Benoist, C., and Mathis, D. (2010). Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. *Immunity* 32, 815–827.
- Xiang, S., Fruehauf, J., and Li, C.J. (2006). Short hairpin RNA-expressing bacteria elicit RNA interference in mammals. *Nat. Biotechnol.* 24, 697–702.
- Yamamoto, S., Wada, J., Katayama, T., Jikimoto, T., Nakamura, M., Kinoshita, S., Lee, K.-M., Kawabata, M., and Shirakawa, T. (2010). Genetically modified Bifidobacterium displaying *Salmonella*-antigen protects mice from lethal challenge of *Salmonella typhimurium* in a murine typhoid fever model. *Vaccine* 28, 6684–6691.
- Yang, L., Nielsen, A.A.K., Fernandez-Rodriguez, J., McClune, C.J., Laub, M.T., Lu, T.K., and Voigt, C.A. (2014). Permanent genetic memory with >1-byte capacity. *Nat. Methods* 11, 1261–1266.
- Yoon, W., Park, Y.C., Kim, J., Chae, Y.S., Byeon, J.H., Min, S.-H., Park, S., Yoo, Y., Park, Y.K., and Kim, B.M. (2017). Application of genetically engineered *Salmonella typhimurium* for interferon-gamma-induced therapy against melanoma. *Eur. J. Cancer* 70, 48–61.
- Zhang, H., Lin, M., Shi, H., Ji, W., Huang, L., Zhang, X., Shen, S., Gao, R., Wu, S., Tian, C., et al. (2014). Programming a Pavlovian-like conditioning circuit in *Escherichia coli*. *Nat. Commun.* 5, 3102.
- Zheng, J.H., Nguyen, V.H., Jiang, S.-N., Park, S.-H., Tan, W., Hong, S.H., Shin, M.G., Chung, I.-J., Hong, Y., Bom, H.-S., et al. (2017). Two-step enhanced cancer immunotherapy with engineered *Salmonella typhimurium* secreting heterologous flagellin. *Sci. Transl. Med.* 9, eaak9537.
- Zhou, Z., Gong, S., Li, X.-M., Yang, Y., Guan, R., Zhou, S., Yao, S., Xie, Y., Ou, Z., Zhao, J., et al. (2015). Expression of *Helicobacter pylori* urease b on the surface of *Bacillus subtilis* spores. *J. Med. Microbiol.* 64, 104–110.